Microneedle Measurable Chronic Disease Biomarkers


prefillable biological drug delivery  Microneedle Measurable Chronic Disease Biomarkers • MCDB329K • June 2022 .   US$3,850


 

 

Biomarkers are a key medical product development tool capable of facilitating development of medical products and spurring innovation. When used in the right context, biomarkers have the potential to help expedite patient access to safe and effective treatments by reducing the time and cost of clinical trials while maintaining patient protections. FDA encourages the integration of biomarkers in medical product development and approval, to facilitate the monitoring of FDA-regulated products, and their appropriate use in clinical practice. Biomarkers promise to reduce stagnation and foster innovation in the development of new medical products. A biomarker can be used as the basis for creating a routine diagnostic test for clinical use, after it has been approved as an in-vitro diagnostic. A biomarker can also be used to develop a companion diagnostic test that enables better decision-making on the use of a therapy that is tailored to the patient.

 

 
 
 
 
 
          
 
 

Microneedle Measurable Chronic Disease Biomarkers – What You Will Learn

• What companies are active in the microneedle diagnostics segments, what distinguishes their technology, and what is their market presence?
• What are the identified and verified chronic disease biomarkers, and what are their properties ?
• What are the major factors that are influencing interest in chronic disease biomarkers?
• What are the design factors, material selection issues, technologies, and market development issues for microneedles capable of capturing and identifying chronic disease biomarkers?
• What are the important therapeutic markets for microneedle measurable chronic disease biomarkers? What is their market potential?
• What are the significant economic, technology, and regulatory factors affecting the market for diagnostic microneedles?

 

 

Summary of Contents

Executive Summary
Microneedle Measurable Chronic Disease Biomarkers
Executive Summary
Point-of-Care Diagnostics Market Dynamics
Biomarkers and their Potential in Clinical Medicine
Microneedles for Detecting and Measuring Biomarkers
Microneedle Product Categories
Solid Microneedles
Hollow Microneedles
Coated Microneedles
Dissolving Microneedles
Stretched Needles
Carbon Nanotubes
Ion Etching
C-MEMS
Specialty Microneedles
Phase Transition
Microprocessor-based Devices
Composite Microneedles
Light-responsive Microneedles
Flexible Arrays
Microneedle Arrays & Array Geometries
Array Architectures
Microneedles & Microfluidics
Wearable Microneedles
The Role of Interstitial Fluid
Microneedle Diagnostics – Design Factors
Analyte Capture
Sample Acquisition
Biofluid Absorption
Electrochemical Sensing Methods
Optical Sensing Methods
Chronic Disease Associated Biomarkers
Biomarker Detection
Microneedle Fabrication
Micromolding
Microforming
Micromachining
Structured Films
Emerging Fabrication Methods
3D Printing
Electrospun Arrays
Two-Photon Polymerization (2PP)
Magnetization-induced Self-assembly
Additive Fabrication Methods
Stereolithography
Fused Deposition Modelling
Digital Light Processing
Selective Laser Sintering
Selective Laser Melting
Inkjet Printing
Surface Modification
Diagnostic Microneedle Device Analysis
Micro Transdermal Interface Platform (MicroTIPs)
Mindera Health
Scibase (Nevisense)
Seventh Sense Biosystems
Sysmex
Chronic Disease Biomarkers
Opportunities Extend Across Numerous Therapeutic Areas
Anesthesiology
Cardiology
Endocrinology
Gastroenterology
Gynecology
Hematology
Inborn Errors of Metabolism
Infectious Diseases
Neurology
Oncology
Rheumatology
Microneedle Biomarker Diagnostics
Key Therapeutic Sectors
Glucose
Immune Factors
Electrolytes/Potassium
Biomarker-enabled Diagnostics
Company Profiles
Market Participant Profiles